LGALS3 and fibrosis: Adding to this, the novel small-molecule inhaled galectin-3 inhibitor, GB0139 (formerly TD139), designed to modulate the fibrogenic response to tissue injury has been shown to decrease galectin-3 expression in the lung and significantly reduce bleomycin-induced fibrosis as assessed by total lung collagen content (28).